Stocks and Investing
Stocks and Investing
Tue, April 16, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, April 15, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Do Kim Maintained (ALNY) at Buy with Increased Target to $126 on, Apr 15th, 2019
Do Kim of BMO Capital, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Increased Target from $119 to $126 on, Apr 15th, 2019.
Do has made no other calls on ALNY in the last 4 months.
There are 3 other peers that have a rating on ALNY. Out of the 3 peers that are also analyzing ALNY, 2 agree with Do's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $70 on, Tuesday, April 9th, 2019
- Esther Rajavelu of "UBS" Initiated at Hold on, Wednesday, January 23rd, 2019
This is the rating of the analyst that currently disagrees with Do
- David Lebovitz of "Morgan Stanley" Upgraded from Hold to Buy on, Tuesday, March 5th, 2019